FOX04-DRI

Overview

FOX04-DRI (widely written as FOXO4-DRI, and referred to in this way throughout the primary literature) is a synthetic peptide designed to interrupt a single, specific protein-protein interaction inside senescent cells: the binding of the transcription factor FOXO4 to the tumour-suppressor protein p53. It was designed and reported by Peter de Keizer's group at Erasmus Medical Centre in Rotterdam, in a paper published in Cell in 2017 that is now regarded as a landmark in the senolytic field. Unlike most peptides discussed on this site, FOX04-DRI was not discovered in nature or adapted from an endogenous hormone; it is a rationally engineered research tool built to exploit a specific vulnerability that de Keizer's team had identified in senescent cells.

The 'DRI' in the name stands for D-retro-inverso, a peptide-engineering strategy in which the amino acid sequence of a biologically active peptide fragment is both reversed (read backwards) and rebuilt entirely from D-amino acids rather than the natural L-amino acids that make up nearly all proteins in biology. This combination is a deliberate trick: a retro-inverso peptide built this way approximately preserves the three-dimensional presentation of the side chains from the original L-peptide, so it can still engage the same binding pocket, but the backbone is now chemically invisible to the proteases that would normally recognise and cut apart an L-peptide chain almost immediately. The result is a peptide that behaves, in terms of shape and target engagement, like the natural FOXO4 fragment it was derived from, but that survives far longer in a biological environment because it resists enzymatic degradation.

FOX04-DRI belongs to the senolytic pharmacology class: compounds designed to selectively kill senescent cells, the damaged, non-dividing cells that accumulate with age and secrete a cocktail of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. Senolytics are a relatively young and heterogeneous category. The best-known members are small-molecule combinations rather than peptides: dasatinib plus quercetin (a tyrosine-kinase inhibitor paired with a flavonoid, first validated as a senolytic pair by Zhu and colleagues in 2015), the flavonoid fisetin, and navitoclax (a Bcl-2-family inhibitor originally developed as a cancer drug). These small molecules generally work by inhibiting anti-apoptotic pathways that senescent cells rely on to resist cell death, broadly termed senescent-cell anti-apoptotic pathways or SCAPs.

FOX04-DRI is mechanistically distinct from all of these. Rather than inhibiting a survival pathway in a general sense, it targets one specific protein-protein interaction that de Keizer's group identified as disproportionately important in senescent cells: the sequestration of p53 by FOXO4. Because this interaction is unusually active in senescent cells (which upregulate FOXO4) and much less relevant in healthy, non-senescent cells, disrupting it in principle offers a route to selectivity that is structurally different from the selectivity mechanisms of dasatinib+quercetin or navitoclax. This is why FOX04-DRI is often described as a 'first-in-class' senolytic peptide, and why it is treated on this site as structurally and mechanistically distinct from anything else in the senolytic or broader longevity-peptide literature. It should be understood, however, that FOX04-DRI remains a research compound derived from a small number of preclinical studies, not an established or licensed therapeutic, and the gap between the original 2017 mouse data and any future human use is considerable.

Mechanism of action

To understand FOX04-DRI, it helps to start with the biology of FOXO4 and p53 in senescent cells specifically. p53 is one of the most extensively studied tumour-suppressor proteins in human biology; among its many roles, it is a central trigger of apoptosis, the controlled process by which a damaged or dangerous cell is instructed to die. Cellular senescence is a state in which a cell permanently stops dividing in response to DNA damage, oncogene activation or other stress, but critically does not die. Senescent cells survive for extended periods, sometimes years, while secreting the SASP factors that drive local and systemic inflammation. A long-standing puzzle in senescence biology has been why senescent cells, despite carrying the kind of DNA damage that would normally activate p53-driven apoptosis in other contexts, manage to avoid dying.

Baar and colleagues' 2017 work provided a specific answer for at least one route: senescent cells upregulate FOXO4, and FOXO4 physically binds to p53 in the nucleus, sequestering it there and preventing p53 from translocating to the mitochondria, where mitochondrial p53 accumulation is required to trigger the intrinsic apoptotic pathway. In effect, elevated FOXO4 acts as a molecular anchor that holds p53 in place and prevents it from carrying out its pro-apoptotic function, allowing the senescent cell to persist despite carrying damage that would normally be lethal. This is the specific survival mechanism that FOX04-DRI was designed to disrupt.

FOX04-DRI works by competitively displacing p53 from FOXO4. The peptide is derived from the region of FOXO4 responsible for binding p53, and because it is present at high enough concentration and resistant to degradation, it competes with endogenous FOXO4 for the same binding surface on p53, freeing p53 from the FOXO4-p53 complex. Once liberated, p53 is able to translocate to the mitochondria and re-engage the intrinsic apoptotic pathway. Because this sequence of events depends on FOXO4 being elevated and available for displacement, the effect is disproportionately concentrated in senescent cells (where FOXO4 is upregulated) relative to healthy, non-senescent cells (where FOXO4 expression and the reliance on FOXO4-p53 sequestration for survival are much lower). This is the proposed basis for the selective, senescent-cell-specific apoptosis reported in the original paper, rather than indiscriminate cytotoxicity across all cell types.

Dosing in the original Baar et al. work was established empirically in mouse models rather than derived from formal human-relevant pharmacokinetic modelling: intraperitoneal administration was used in both fast-ageing (XpdTTD/TTD) and naturally aged mice, at doses in the low milligram-per-kilogram range, typically several times per week over periods of weeks. The D-retro-inverso design was specifically chosen to allow the peptide to survive long enough after injection to reach and engage its target before being cleared, which is a substantial part of why the retro-inverso strategy was used rather than the native L-peptide fragment, which would be expected to degrade far more rapidly in circulation. A subsequent structural-biology paper by Bourgeois and colleagues (Nature Communications, 2025) has refined the mechanistic picture further, describing how the interaction centres on the intrinsically disordered transactivation domain of p53 rather than a conventional folded binding pocket — a finding consistent with, and mechanistically sharpening, the original 2017 model.

The specificity argument for FOX04-DRI rests on relative expression rather than an absolute biological switch. FOXO4 is expressed at some level throughout the body, and the FOXO4-p53 interaction is not a phenomenon unique to senescent cells in a binary sense; it is a matter of degree, with senescent cells relying on markedly elevated FOXO4 to sustain a survival advantage that healthy cells do not need in the same way. This means the selectivity reported in mouse studies is best understood as a favourable therapeutic window rather than a mechanism that makes off-target effects in non-senescent, FOXO4-expressing tissue structurally impossible. This distinction matters when comparing FOX04-DRI to small-molecule senolytics, whose selectivity is grounded in different biology (dependence on specific anti-apoptotic pathways) and therefore carries a different, but not necessarily smaller, set of off-target considerations.

Research history

FOX04-DRI originates from the laboratory of Peter de Keizer, then at Erasmus Medical Centre in Rotterdam, as part of a broader research programme into the molecular basis of cellular senescence and its role in ageing and age-related tissue dysfunction. The 2017 Cell paper by Baar, Brandt, Putavet and colleagues, working with senior authors including Jan Hoeijmakers, Judith Campisi and de Keizer, described both the discovery of the FOXO4-p53 interaction as a senescent-cell survival mechanism and the design and testing of FOX04-DRI as a tool to disrupt it. The paper reported that FOX04-DRI treatment in aged and fast-ageing mouse models restored fitness, fur density and renal function, and reduced markers of senescence in multiple tissues, without evidence of toxicity to healthy cells over the treatment period studied.

The 2017 publication generated substantial attention both within the senescence research community and in general science media, partly because of the visually striking fur-density and mobility improvements reported in treated mice, and partly because it offered a mechanistically distinct alternative to the small-molecule senolytics (dasatinib+quercetin, navitoclax, fisetin) that dominated the field at the time. Independent groups subsequently applied FOX04-DRI in more specific contexts: for example, Zhang and colleagues (Aging, 2020) reported that FOX04-DRI cleared senescent Leydig cells in aged mice and improved age-related declines in testosterone secretion, extending the original findings to a specific endocrine-ageing phenotype. Structural work by Bourgeois and colleagues (Nature Communications, 2025) has since refined the biophysical basis of the FOXO4-p53-FOX04-DRI interaction using NMR spectroscopy, sharpening understanding of exactly how the peptide displaces p53's disordered transactivation domain.

Commercial translation of the underlying science has been pursued by Cleara Biotech, a company co-founded by de Keizer to develop senolytic therapeutics building on the FOXO4-p53 mechanism. As of 2026, publicly available information indicates that Cleara's clinical development focus has shifted toward optimised proprietary analogue compounds (rather than FOX04-DRI in its original 2017 form) as candidates for early-phase human trials, with disease targets under discussion including chronic conditions such as osteoarthritis, chronic obstructive pulmonary disease and chronic kidney disease. The original FOX04-DRI peptide itself has not, as of 2026, entered registered human clinical trials; it remains a preclinical research tool whose in vivo evidence base is still substantially built on the original 2017 mouse study together with a small number of later mechanistic and disease-model follow-ups.

Summarised studies